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A recent article deals with promising use of irinotecan in treatment of Angelman Syndrome, a                             
neurological disorder. The present report provides mechanistic evidence for involvement of electron                       
transfer based on preliminary data from computational studies on electron affinity. The drug and the                             
topotecan analog are related to camptothecin, a well­known anticancer drug. The protonated forms are                           
better at electron affinity. Lactone hydrolysis may provide carboxyl for intramolecular protonation.                       
The active phenol metabolits may also play a role. Structure­activity relationship (SAR) in addressed.                           
These results buttress the prior hypothesis dealing with irinotecan mechanism in central nervous system                           
toxicity. 
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About a dozen years ago, a mechanism was proposed for the central nervous system toxicity by                               
irinotecan (CPT­11) (Fig. 1) [1]. The proposal was an outgrowth of a report on the toxicity [2].                                 
CPT­11, a semi­synthetic derivative of camptothecin (CTT) (Fig. 2), is used primarily in treatment of                             
colon related cancer. Concerning the basic mode of action of CTT, much evidence exists for                             
participation of electron transfer (ET), reactive oxygen species (ROS) and oxidative stress (OS) (3).                           
Much of the rationale for mode of action is based on evidence from studies on the parent, anti­cancer                                   
drug CTT. 
Many physiological responses involve bioactive substances or their metabolites which contain                     
ET functional groups, such as quinones (or phenolic precursors), metal­containing substances, aromatic                       
nitro compounds (or reduced metabolites) and conjugated imine or iminium species. The last category                           
is the main focus of the present review. Schemes 1 and 2 portray redox cycling with generation of                                   
ROS. Redox cycling in vivo can occur when the ET agent has a reduction potential greater than ­0.5 V                                     
which falls in the permissive range. A significant aspect is ROS concentration with higher levels                             
producing toxicity and with lower levels being able to generate beneficial results.  
Previous reports provide evidence for involvement of ROS, reactive nitrogen species (RNS),                       
oxidative stress (OS) and antioxidants (AOs) in the bioactivation of anti­infective agents [4],                         
anti­cancer agents [5], carcinogens [6], and toxins (toxicants) [7­19]. There is considerable evidence                         
demonstrating that these unifying mechanistic concepts are applicable to the present review.  
There is a plethora of experimental evidence supporting the theoretical framework, including                       
generation of common ROS, lipid peroxidation, degradation products of oxidation, depletion of AOs,                         
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This comprehensive, unifying mechanism is in keeping with the frequent observations that many ET                           
substances display a variety of activities, e.g., multiple drug properties, as well as toxic effects.  
A recent report broadly links neurotoxicity to ET­ROS­OS [20], within which framework there                         
is a fit with CTT serving as a model. ET can occur in the biodomain with CTT in protonated form                                       
according to electrochemical evidence [3]. The extensive conjugation of the radical anion favors                         
stabiliaztion of the quinolinium ion which incorporates an attached planar structure. Pyridinuim                       
aromatic character is associated with the N­alkyl­2­ pyridone portion. Electrochemical data reveal that                         
CTT in protonated form possesses a reduction potential amenable to ET in the biological milieu [3].                               
The quinolinium ion (iminium­like) is part of extensive conjugation, making for resonance stabilization                         
of the ensuing radical. Regions of CTT associated with activity include the conjugated, planar, ring                             
system which can be related to ET and site binding. The N­alkyl­2­pyridone portion displays aromatic                             
character related to pyridinium.   
The phenolic metabolite which has been designated the active form [1], has the same core                             
structure capable of ET. Also, it may be a precursor of a quinone­imine structure analogous to that                                 
(Fig. 3) derived from ellipticines [5]. Several investigations link ET with antineoplastic activity of                           
CTT [3]. A review on mechanism of anticancer drugs provides evidence of involvement of                           
ET–ROS–OS [5]. ROS participation also appears to occur with CTT [3]. A number of reports indicate                               
ROS involvement for CTT [3].  
A 2011 article involves use of irinotecan in people with Angelman syndrome, a serious                           
neurological disorder [21]. In a screening of 2306 compounds from drug libraries, CPT­11 was the                             
only one which reactivates the Ube 3A gene and prevents DNA from unwinding. The mechanistic                             
aspects are unclear. In the patients, the genetic defect results in speech loss, intellectual malfunction,                             
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topotecan (Fig. 4), a structurally related anticancer drug, there are encouraging signs of a long­lasting                             
effect in treatment of the CNS illness. Genes were associated with irinotecan pharmacokinetics in                           
cancer patients [22]. 
Preliminary data are now provided to buttress the hypothesis in the form of computational                           
studies involving electron affinity [EA]. Structure­activity relationship is discussed. Increasing                   
evidence supports a multifaceted approach to drug action. Hence, it is reasonable to apply the                             
ET­ROS­OS mechanism to CPT­11 action in Angelman Syndrome, which provides added support to                         
the prior hypothesis [1].  
Electron affinity  
The electron uptake efficiency of an ET agent is strongly correlated to its electron affinity                             
(EA). Electron affinity is usually expressed as the inverse enthalpy change (­ΔH) for the process A+e­                               
 A­. The electron uptake is determined by the free energy (ΔG) for this electron attachment, which is                                 
related to the EA at any given temperature (T) by ΔG= ΔH­T ΔS = EA ­T ΔS (ΔS= entropy change).                                       
However, because ΔS for this process is roughly independent of the electron acceptor (A), the free                               
energy for the electron uptake is determined almost entirely by the EA. Electron affinities for many                               
organic electron acceptors were obtained by directly measuring electron absorption coefficients in                       
electron­rich environments. 
Prior EA values are available [23] for prominent ET functionalities, such as quinones (0.54­                           
0.64 eV) and aromatic nitro compounds (0.59 eV for dinitrophenol). EA values were also calculated for                               
amphotericin B, a macrolide polyene antibiotic. The drug, which incorporates seven conjugated alkene                         
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We have calculated the gas­phase EA of irinotecan using density functional calculations, in                         
order to establish whether it is likely to serve as a viable ET agent. Calculations were carried out using                                     
the B3LYP method and Dunnings’s cc­pVDZ basis set [24­26], running under Gaussian 09 [27] on a                               
Linux cluster. We determined EA values of 1.5 eV for neutral irinotecan and 5.4 eV for its protonated                                   
form at 298 K.  The G values are predicted to differ from the H values by less than 0.1 eV.   
Considerable attention has been devoted to metabolism, including hydrolysis of the lactone and                         
sidechain ester portions of CTT and analogs catalyzed by esterases [28­50]. There is scant discussion                             
of mechanistic impact. A hypothesis is presented herein concerning the role in bioactivity. An article a                               
few years ago states that the key structural requirement for the antitumor activity in                           
10­hydroxycamptothecin is the intact lactone moiety [28]. Potent antitumor activity of the                       
camptothecin class is known to be lost upon opening of the lactone ring [29]. In view of the above                                     
discussion, it may be that the open ring metabolites, although active, cannot reach the active site due to                                   
unfavorable pharmacokinetics or in inactive carboxylate, rather than carboxyl form. Various articles                       
document the favorable influence of lactone hydrolysis. Carboxyesterases form active metabolites                     
from this class by ring opening, resulting in potent inhibition of topoisomerase I [30­47].  
According to our hypothetical approach, the conjugated polynuclear system plays a key role in                           
ET. The EA calculations (see above) indicate that the protonated form of this entity operates much                               
better in electron attraction than the parent base. Hence, it is conceivable that lactone ring opening                               
provides a proton for intramolecular cation generation from the basic quinoline portion. The proton                           
might be donated by the carboxyl group from hydrolysis. Alternatively, if lactone cleavage is catalyzed                             
by proton, followed by nucleophilic attack by water, nitrogen cation formation may involve protonated                           
carboxyl. A conformation illustrated in Fig. 5 shows the carboxyl hydrogen in close proximity to the                               
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carboxyl, thus increasing aromaticity of the N­heterocylce. The tertiary­alcohol may hydrogen bond                       
with carboxyl carbonyl. The phenolic metabolite (37, 38), potential precursor of iminoquinone (Fig. 3)                           
has been designated the active form (see above).   
Other Relevant Data 
Cyclic voltammetry data, provided on analogous conjugated quinolinium salts, lent credence to                       
the ET­ROS­OS approach (48). Related studies based on computation (49) and reduction potentials                         
(50), involving benzodiazepines, support the ET­ROS­OS unifying mechanism.  
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